Loading clinical trials...
Loading clinical trials...
CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma
Conditions
Interventions
CD19-targeted CAR-T cells
Locations
1
China
The west area of the First Affiliated Hospital of University of Science & Technology China
Hefei, Anhui, China
Start Date
April 10, 2018
Primary Completion Date
April 10, 2019
Completion Date
April 20, 2019
Last Updated
April 10, 2018
NCT06263491
NCT07388563
NCT06337318
NCT05529069
NCT05139017
NCT07350863
Lead Sponsor
Sinobioway Cell Therapy Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions